Incannex Healthcare Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Incannex Healthcare Inc. (IXHL) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $56.51 million for the 9-month period ending 2026-03-31, per its 10-Q filed 2026-05-15.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-05-15
- Incannex Healthcare Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-09-30 was $57.97M.
- Incannex Healthcare Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-09-30 was -$2.25M.
- Incannex Healthcare Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $8.88M.
- Incannex Healthcare Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$16.12M.
- Incannex Healthcare Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$2.89M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|---|
| 2026-03-31 | $56.51M 10-Q · filed 2026-05-15 | ||||
| 2025-12-31 | $54.27M 10-Q · filed 2026-02-13 | ||||
| 2025-09-30 | $57.97M 10-Q · filed 2025-11-14 | ||||
| 2025-06-30 | $8.88M 10-K · filed 2025-09-29 | ||||
| 2025-03-31 | $755.00K 10-Q · filed 2026-05-15 | ||||
| 2024-12-31 | -$3.83M 10-Q · filed 2026-02-13 | ||||
| 2024-09-30 | -$2.25M 10-Q · filed 2025-11-14 | ||||
| 2024-06-30 | -$16.12M 10-K · filed 2025-09-29 | ||||
| 2024-03-31 | -$12.45M 10-Q · filed 2025-05-15 | -$12.48M 10-Q · filed 2024-05-15 | |||
| 2023-12-31 | -$8.13M 10-Q · filed 2025-02-14 | ||||
| 2023-06-30 | -$2.89M 10-K · filed 2024-09-30 | ||||
| 2023-03-31 | -$105.00K 10-Q · filed 2024-05-15 | ||||
| 2022-12-31 | $2.73M 10-Q · filed 2024-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B |